Cargando…

Catalytic Inhibitors of Topoisomerase II Differently Modulate the Toxicity of Anthracyclines in Cardiac and Cancer Cells

Anthracyclines (such as doxorubicin or daunorubicin) are among the most effective anticancer drugs, but their usefulness is hampered by the risk of irreversible cardiotoxicity. Dexrazoxane (ICRF-187) is the only clinically approved cardioprotective agent against anthracycline cardiotoxicity. Its act...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vavrova, Anna, Jansova, Hana, Mackova, Eliska, Machacek, Miloslav, Haskova, Pavlina, Tichotova, Lucie, Sterba, Martin, Simunek, Tomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3792022/ https://www.ncbi.nlm.nih.gov/pubmed/24116135 http://dx.doi.org/10.1371/journal.pone.0076676

Ejemplares similares

Quantitative Analysis of the Anti-Proliferative Activity of Combinations of Selected Iron-Chelating Agents and Clinically Used Anti-Neoplastic Drugs
por: Potuckova, Eliska, et al.
Publicado: (2014)

In Vitro Characterization of the Pharmacological Properties of the Anti-Cancer Chelator, Bp4eT, and Its Phase I Metabolites
por: Potůčková, Eliška, et al.
Publicado: (2015)

Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity
por: Bavlovič Piskáčková, Hana, et al.
Publicado: (2021)

Examination of diverse iron-chelating agents for the protection of differentiated PC12 cells against oxidative injury induced by 6-hydroxydopamine and dopamine
por: Hašková, Pavlína, et al.
Publicado: (2022)

Structure-Activity Relationships of Novel Salicylaldehyde Isonicotinoyl Hydrazone (SIH) Analogs: Iron Chelation, Anti-Oxidant and Cytotoxic Properties
por: Potůčková, Eliška, et al.
Publicado: (2014)

Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death
por: Popelová, O, et al.
Publicado: (2009)

Esters of terpene alcohols as highly potent, reversible, and low toxic skin penetration enhancers
por: Kopečná, Monika, et al.
Publicado: (2019)

Protective Effects of D-Penicillamine on Catecholamine-Induced Myocardial Injury
por: Říha, Michal, et al.
Publicado: (2016)

Molecular Remodeling of Left and Right Ventricular Myocardium in Chronic Anthracycline Cardiotoxicity and Post-Treatment Follow Up
por: Lenčová-Popelová, Olga, et al.
Publicado: (2014)

Anthracyclines as Topoisomerase II Poisons: From Early Studies to New Perspectives
por: Marinello, Jessica, et al.
Publicado: (2018)

Proline, hydroxyproline, and pyrrolidone carboxylic acid derivatives as highly efficient but reversible transdermal permeation enhancers
por: Kopečná, Monika, et al.
Publicado: (2022)

Menogaril, an Anthracycline Derivative, Inhibits DNA Topoisomerase II by Stabilizing Cleavable Complexes
por: Ono, Katsuhiro, et al.
Publicado: (1992)

Discovery of New Catalytic Topoisomerase II Inhibitors for Anticancer Therapeutics
por: Matias-Barrios, Victor M., et al.
Publicado: (2021)

Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents
por: Sestak, Vit, et al.
Publicado: (2015)

Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin
por: Jong, R S de, et al.
Publicado: (1999)

Regulation of the catalytic function of topoisomerase II alpha through association with RNA
por: Park, Seung-Won, et al.
Publicado: (2008)

Non-Catalytic Roles of the Topoisomerase IIα C-Terminal Domain
por: Clarke, Duncan J., et al.
Publicado: (2017)

Optimization of New Catalytic Topoisomerase II Inhibitors as an Anti-Cancer Therapy
por: Matias-Barrios, Victor M., et al.
Publicado: (2021)

Radiotherapy and anthracyclines – cardiovascular toxicity
por: Mozdzanowska, Dagmara, et al.
Publicado: (2014)

Topoisomerase II alpha and TLE3 as predictive markers of response to anthracycline and taxane-containing regimens for neoadjuvant chemotherapy in breast cancer
por: Susini, Tommaso, et al.
Publicado: (2014)

Comparative Cardiac Toxicity of Anthracyclines In Vitro and In Vivo in the Mouse
por: Toldo, Stefano, et al.
Publicado: (2013)

Cardiac Toxicity and Anthracyclines: Mechanism, Interventions, and the Trouble With Troponin
por: Thompson, Grace E., et al.
Publicado: (2019)

HMGB1 interacts with human topoisomerase IIα and stimulates its catalytic activity
por: Štros, Michal, et al.
Publicado: (2007)

Substituted 4,5′-Bithiazoles as Catalytic Inhibitors of Human DNA Topoisomerase IIα
por: Bergant Loboda, Kaja, et al.
Publicado: (2020)

Catalytic Mechanism of ATP Hydrolysis in the ATPase Domain of Human DNA Topoisomerase IIα
por: Ogrizek, Mitja, et al.
Publicado: (2022)

Phosphate-Based Self-Immolative Linkers for the Delivery of Amine-Containing Drugs
por: Đud, Mateja, et al.
Publicado: (2021)

Selenium in the Prevention of Anthracycline-Induced Cardiac Toxicity in Children with Cancer
por: Tacyildiz, Nurdan, et al.
Publicado: (2012)

Circulating hemopexin modulates anthracycline cardiac toxicity in patients and in mice
por: Liu, Jing, et al.
Publicado: (2022)

Cell Cycle–coupled Relocation of Types I and II Topoisomerases and Modulation of Catalytic Enzyme Activities
por: Meyer, Kay N., et al.
Publicado: (1997)

Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogue
por: Chène, Patrick, et al.
Publicado: (2009)

Catalytic Core of Human Topoisomerase IIα: Insights into Enzyme–DNA Interactions and Drug Mechanism
por: Lindsey, R. Hunter, et al.
Publicado: (2014)

Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor signaling and prostate cancer progression
por: Li, Haolong, et al.
Publicado: (2015)

Exploration of the Role of the C-Terminal Domain of Human DNA Topoisomerase IIα in Catalytic Activity
por: Dougherty, Ashley C., et al.
Publicado: (2021)

DNA-Stimulated Liquid-Liquid phase separation by eukaryotic topoisomerase ii modulates catalytic function
por: Jeong, Joshua, et al.
Publicado: (2022)

Phenotypic Discovery of Thiocarbohydrazone with Anticancer Properties and Catalytic Inhibition of Human DNA Topoisomerase IIα
por: Cvijetić, Ilija N., et al.
Publicado: (2023)

Preparation of Substituted Methyl o-Nitrophenyl Sulfides
por: Dudova, Katerina, et al.
Publicado: (2002)

BCL-2, topoisomerase IIα, microvessel density and prognosis of early advanced breast cancer patients after adjuvant anthracycline-based chemotherapy
por: Biesaga, Beata, et al.
Publicado: (2014)

Topoisomerase II α Gene alteration in Triple Negative Breast Cancer and Its Predictive Role for Anthracycline-Based Chemotherapy (Egyptian NCI Patients)
por: Eltohamy, Mahitab Ibrahim, et al.
Publicado: (2018)

Topoisomerase 2 alpha as a predictor of response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer
por: Shehata, M, et al.
Publicado: (2010)

Nitric oxide and cytokine production by glial cells exposed in vitro to neuropathogenic schistosome Trichobilharzia regenti
por: Macháček, Tomáš, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_agdcb7304m586kue61eq3g2nlk